← All stocks

4D Molecular Therapeutics, Inc.

FDMT Net buying
CIK 0001650648 #2652 in the set updated 17 Sep 2026
Bought (120 mo)
$51.07M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$28.82M
$7.67M on a plan · $4.37M straight out of an exercise
Sold at will
$16.79M
24 of 92 sales
Net
+$22.25M
+$34.29M against sales at will

By person

14 insiders · 101 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
VIKING GLOBAL INVESTORS LP entity
10% owner
$38.90M (2)
$10.55M (1)
+$28.35M
8,185,828
14.83%
$113.81M
+107.9%
Kirn David
See Remarks
$12.53M (28) scheduled
−$12.53M
1,367,486
2.48%
$19.01M
−31.6%
YAO TONY DUNG LING
Director
$9.78M (1)
+$9.78M
1,063,744
1.93%
$14.79M
SCHAFFER DAVID
Director
$3.01M (13)
−$3.01M
901,215
1.63%
$12.53M
−9.9%
MILLIGAN JOHN F
Director
$2.30M (1)
+$2.30M
100,000
0.1811%
$1.39M
Bizily Scott
Chief Legal Officer
$1.89M (41) scheduled
−$1.89M
8,617
0.0156%
$119.80K
−46.6%
Kim Robert Young
Chief Medical Officer
$737.79K (4) scheduled
−$737.79K
1,043
0.0019%
$14.50K
−34.6%
Chacko Jacob
Director
$100.27K (1) scheduled
−$100.27K
0
0.0000%
$0.00
Kamal Fariborz
President & COO
$99.98K (1)
+$99.98K
4,347
0.0079%
$60.44K
Gupta Ashoo
VP, Finance and Controller
$6.73K (4) scheduled
−$6.73K
47,055
0.0852%
$654.21K
+3.1%
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
4,563,211
8.26%
$63.44M
−10.5%
BVF PARTNERS L P/IL entity
See Explanation of Responses
87,911
0.1592%
$1.22M
−98.5%
THEUER CHARLES
Director
41,684
0.0755%
$579.53K
+28.8%
Moretti August J
Chief Financial Officer
11,045
0.0200%
$153.56K
+173.1%
Insider
Date
Role
Action
Shares
Price
Amount
VIKING GLOBAL INVESTORS LP
9 May 2023
10% owner
Buy indirect
850,000
$16.00
$13.60M
YAO TONY DUNG LING
15 Dec 2020
Director
Buy indirect
425,000
$23.00
$9.78M
Kamal Fariborz
15 Dec 2020
See Remarks
Buy
4,347
$23.00
$99.98K
MILLIGAN JOHN F
15 Dec 2020
Director
Buy indirect
100,000
$23.00
$2.30M
VIKING GLOBAL INVESTORS LP
15 Dec 2020
10% owner
Buy indirect
1,100,000
$23.00
$25.30M

What was left out

Form 4 filings counted 139
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 5
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 52
Sales at will 24
Transactions with no price 0
Shares from compensation/vesting 11,097,993
Sales filed before the plan box existed 22
History held since 17 Dec 2020